Abstract:The anti-angiogenic soluble fms-like tyrosine kinase 1 (sFLT1) is one of the candidates in the progression of preeclampsia, often associated with fetal growth restriction (FGR). Therapeutic agents against preeclampsia with/without FGR, as well as adequate transgenic sFLT1 mouse models for testing such agents, are still missing. Much is known about sFLT1–mediated endothelial dysfunction in several tissues; however, the influence of sFLT1 on placental and fetal development is currently unknown. We hypothesize that sFLT1 is involved in the progression of FGR by influencing placental differentiation and vascularization and is a prime candidate for interventional strategies. Therefore, we generated transgenic inducible human sFLT1/reverse tetracycline-controlled transactivator (hsFLT1/rtTA) mice, in which hsFLT1 is ubiquitously overexpressed during pregnancy in dams and according to the genetics in hsFLT1/rtTA homozygous and heterozygous fetuses. Induction of hsFLT1 led to elevated hsFLT1 levels in the serum of dams and on mRNA level in all placentas and hetero-/homozygous fetuses, resulting in FGR in all fetuses at term. The strongest effects in respect to FGR were observed in the hsFLT1/rtTA homozygous fetuses, which exhibited the highest hsFLT1 levels. Only fetal hsFLT1 expression led to impaired placental morphology characterized by reduced placental efficiency, enlarged maternal sinusoids, reduced fetal capillaries, and impaired labyrinthine differentiation, associated with increased apoptosis. Besides impaired placental vascularization, the expression of several transporter systems, such as glucose transporter 1 and 3 (Glut-1; Glut-3); amino acid transporters, solute carrier family 38, member one and two (Slc38a1; Slc38a2); and most severely the fatty acid translocase Cd36 and fatty acid binding protein 3 (Fabp3) was reduced upon hsFLT1 expression, associated with an accumulation of phospholipids in the maternal serum. Moreover, the Vegf pathway showed alterations, resulting in reduced Vegf, Vegfb, and Plgf protein levels and increased Bad and Caspase 9 mRNA levels. We suggest that hsFLT1 exerts an inhibitory influence on placental vascularization by reducing Vegf signaling, which leads to apoptosis in fetal vessels, impairing placental differentiation, and the nutrient exchange function of the labyrinth. These effects were more pronounced when both the dam and the fetus expressed hsFLT1 and ultimately result in FGR and resemble the preeclamptic phenotype in humans.

Sirtuin 1 is a potential therapeutic candidate gene for fetal growth restriction via insulin-like 4

Fetal Growth Restriction: Does an Integrated Maternal Hemodynamic-Placental Model Fit Better?

Mir-373-3p Regulates the Proliferative and Migratory Properties of Human HTR8 Cells Via SLC38A1 Modulation

An miRNA-mRNA integrative analysis in human placentas and mice: role of the Smad2/miR-155-5p axis in the development of fetal growth restriction

Integrated Bioinformatics Analysis to Screen Hub Gene Signatures for Fetal Growth Restriction

Mirna-210-3p Regulates Trophoblast Proliferation and Invasiveness Through Fibroblast Growth Factor 1 in Selective Intrauterine Growth Restriction

CircTHBS1 Promotes Trophoblast Cell Migration and Invasion and Inhibits Trophoblast Apoptosis by Regulating Mir-136-3p/igf2r Axis

The placental blood perfusion and LINC00473-mediated promotion of trophoblast apoptosis in fetal growth restriction

Mid-pregnancy placental transcriptome in a model of placental insufficiency with and without novel intervention

Mir-141 Contributes To Fetal Growth Restriction By Regulating Plag1 Expression

Maternal-fetal interfaces transcriptome changes associated with placental insufficiency and a novel gene therapy intervention

miR-1227-3p participates in the development of fetal growth restriction via regulating trophoblast cell proliferation and apoptosis

Down-regulation of placental folate transporters in intrauterine growth restriction

FGR-associated Placental Insufficiency and Capillary Angiogenesis Involves Disruptions in Human Placental Mirnas and Mrnas

MicroRNA Expression Profiles and Networks in Placentas Complicated with Selective Intrauterine Growth Restriction.

[A Study on the Relationship Between Insulin-Like Growth Factor, Insulin-Like Growth Factor-Binding Protein-3 and Fetal Growth Retardation].

Integrated Analysis of Key Genes and Pathways Involved in Fetal Growth Restriction and Their Associations With the Dysregulation of the Maternal Immune System

Insulin-like growth factor 1 signaling in the placenta requires endothelial nitric oxide synthase to support trophoblast function and normal fetal growth

Human sFLT1 Leads to Severe Changes in Placental Differentiation and Vascularization in a Transgenic hsFLT1/rtTA FGR Mouse Model

Mir-181D-5p, Which is Upregulated in Fetal Growth Restriction Placentas, Inhibits Trophoblast Fusion Via CREBRF.